Testing New Drug Combinations Before Lung Cancer Surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-squamous non-small cell lung cancer (a common type of lung cancer) that can be completely removed by surgery
- Your cancer is Stage II–IIIB with spread to lymph nodes in the chest (N2 disease)
- Your cancer has an EGFR mutation (a specific genetic change) and does not have certain other genetic mutations
- You have not received any prior chemotherapy, immunotherapy, or targeted therapy for lung cancer
- You are in good overall health with an ECOG score of 0 or 1 (able to do light activities)
- You do not have a history of interstitial lung disease or pneumonitis (lung inflammation), or it has been ruled out by imaging
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with 2 or 4 cycles of chemotherapy before surgery can help shrink tumors and improve outcomes for people with early-stage (stage II-IIIB) non-small cell lung cancer. The goal is to make surgery more effective and possibly reduce the chance of cancer coming back.
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
This trial tests whether giving a combination of two drugs (sintilimab and anlotinib) before surgery can help shrink non-small cell lung cancer tumors and improve outcomes. It is for people with stage IB to IIIB cancer that can be removed with surgery and who have not had treatment yet.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.